Resolution of Lancisi's sign following bicaval TricValve implantation for torrential tricuspid regurgitation: a case report defining a novel bedside marker of haemodynamic recovery.
- 1Department of Cardiology, TOBB University of Economics and Technology Faculty of Medicine, Yaşam Cad. No: 5, Söğütözü, Ankara 06560, Türkiye.
Abstract
Caval valve implantation (CAVI) using the TricValve system is an emerging treatment option for severe tricuspid regurgitation (TR) in patients who are unsuitable for surgery or orthotopic transcatheter intervention. Lancisi's sign is a classical manifestation of severe TR; however, its resolution after CAVI has not been described. An 85-year-old woman with recurrent right heart failure and torrential TR presented with prominent bilateral Lancisi's sign. Echocardiography revealed severe annular dilatation (48 mm), right ventricular dysfunction (TAPSE, 13 mm), and a left ventricular ejection fraction of 40%. Owing to prohibitive surgical risk (EuroSCORE II 18.4%; TRI SCORE 14), she underwent successful implantation of 29-mm superior vena cava and 35-mm inferior vena cava TricValve prostheses. At 3 months, Lancisi's sign had completely resolved, NYHA functional class improved from III-IV to I-II, NT-proBNP decreased from 25 000 to 2 000 pg/mL, TAPSE increased from 13 to 20 mm, and no rehospitalization or device-related adverse event occurred. We report a structured single-patient case using clinical examination, echocardiography, invasive hemodynamic assessment, laboratory markers, and 3-month follow-up after bicaval TricValve implantation. Bicaval TricValve implantation resulted in marked symptomatic, biochemical, echocardiographic, and bedside clinical improvements. The resolution of Lancisi's sign may represent a simple marker of hemodynamic recovery after CAVI.
Related
- Transcatheter Aortic Valve Implantation in Complex Anatomy: An Anatomy-Driven Framework for Bicuspid Stenosis, Pure Aortic Regurgitation, and the Small Annulus in the Era of Lifetime Management
- Clinical Impact of Multiple‐Clip Implantation for Residual Mitral Regurgitation After Transcatheter Edge‐to‐Edge Repair
- Multifocal Posterior Pigment Epitheliopathy in a Pachychoroid Eye Following Ahmed Glaucoma Valve Implantation: A Case Report
- Impact of prolonged balloon inflation on valve expansion and early clinical outcomes following contemporary balloon-expandable transcatheter aortic valve implantation
- Longitudinal Changes in Anxiety and Depression Following First Implantable Cardioverter-Defibrillator Implantation: A Prospective Observational Study
BibTeX
@article{asfour2026resolution,
title = {{Resolution of Lancisi's sign following bicaval TricValve implantation for torrential tricuspid regurgitation: a case report defining a novel bedside marker of haemodynamic recovery.}},
author = {Mohamed Asfour and Huseyin Bozbas},
journal = {European heart journal. Case reports},
year = {2026},
month = oct,
doi = {10.1093/ehjcr/ytag735},
url = {https://europepmc.org/article/MED/42953770},
note = {CC BY},
}
RIS
TY - JOUR
TI - Resolution of Lancisi's sign following bicaval TricValve implantation for torrential tricuspid regurgitation: a case report defining a novel bedside marker of haemodynamic recovery.
AU - Mohamed Asfour
AU - Huseyin Bozbas
PY - 2026
DA - 2026/10/17
JO - European heart journal. Case reports
DO - 10.1093/ehjcr/ytag735
UR - https://europepmc.org/article/MED/42953770
AB - Caval valve implantation (CAVI) using the TricValve system is an emerging treatment option for severe tricuspid regurgitation (TR) in patients who are unsuitable for surgery or orthotopic transcatheter intervention. Lancisi's sign is a classical manifestation of severe TR; however, its resolution after CAVI has not been described. An 85-year-old woman with recurrent right heart failure and torrential TR presented with prominent bilateral Lancisi's sign. Echocardiography revealed severe annular dilatation (48 mm), right ventricular dysfunction (TAPSE, 13 mm), and a left ventricular ejection fraction of 40%. Owing to prohibitive surgical risk (EuroSCORE II 18.4%; TRI SCORE 14), she underwent successful implantation of 29-mm superior vena cava and 35-mm inferior vena cava TricValve prostheses. At 3 months, Lancisi's sign had completely resolved, NYHA functional class improved from III-IV to I-II, NT-proBNP decreased from 25 000 to 2 000 pg/mL, TAPSE increased from 13 to 20 mm, and no rehospitalization or device-related adverse event occurred. We report a structured single-patient case using clinical examination, echocardiography, invasive hemodynamic assessment, laboratory markers, and 3-month follow-up after bicaval TricValve implantation. Bicaval TricValve implantation resulted in marked symptomatic, biochemical, echocardiographic, and bedside clinical improvements. The resolution of Lancisi's sign may represent a simple marker of hemodynamic recovery after CAVI.
SN - 2514-2119
ER -